Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

G Bozzi, D Mangioni, F Minoia, S Aliberti… - Journal of Allergy and …, 2021 - Elsevier
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress …
被引用次数：113 相关文章

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

G Bozzi, D Mangioni, F Minoia… - The Journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2-induced cytokine storm, which drives acute respiratory distress …

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

G Bozzi, D Mangioni, F Minoia, S Aliberti… - Journal of Allergy and …, 2021 - jacionline.org
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress …

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study

G Bozzi, D Mangioni, F Minoia, S Aliberti… - … OF ALLERGY AND …, 2021 - air.unimi.it
Background Immunomodulants have been proposed to mitigate SARS-Cov-2-induced
cytokine storm, which drives acute respiratory distress syndrome in COVID-19. Objective To …

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.

G Bozzi, D Mangioni, F Minoia, S Aliberti… - The Journal of Allergy …, 2020 - europepmc.org
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2-induced cytokine storm, which drives acute respiratory distress …

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study

G Bozzi, D Mangioni, F Minoia, S Aliberti… - … OF ALLERGY AND …, 2021 - iris.hunimed.eu
Background Immunomodulants have been proposed to mitigate SARS-Cov-2-induced
cytokine storm, which drives acute respiratory distress syndrome in COVID-19. Objective To …
[HTML] nih.gov

[HTML][HTML] Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

G Bozzi, D Mangioni, F Minoia, S Aliberti… - The Journal of Allergy …, 2021 - ncbi.nlm.nih.gov
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2–induced cytokine storm, which drives acute respiratory distress …

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.

G Bozzi, D Mangioni, F Minoia, S Aliberti, G Grasselli… - 2021 - cabidigitallibrary.org
Background: Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2-induced cytokine storm, which drives acute respiratory distress …

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.

G Bozzi, D Mangioni, F Minoia, S Aliberti… - The Journal of Allergy …, 2020 - europepmc.org
Background Immunomodulants have been proposed to mitigate severe acute respiratory
syndrome coronavirus 2-induced cytokine storm, which drives acute respiratory distress …